|Bid||82.14 x 900|
|Ask||82.15 x 800|
|Day's range||81.38 - 91.00|
|52-week range||81.38 - 232.76|
|Beta (5Y monthly)||0.97|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||119.33|
This year's big pullbacks are more the result of a raucous 2020, and less an indictment of these companies' prospects.
NovoCure (NASDAQ: NVCR) was one of the better-performing stocks of early 2021, but the big gains came to an end in June. Is the recent plunge an opportunity to buy a great medical device stock on sale, or is it the beginning of a longer slide? NovoCure's flagship product, Optune, is a weird-looking, battery-powered hat that generates electric fields in order to disrupt cancer cell division.
ST. HELIER, Jersey, November 23, 2021--Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.